Document is current
Any future updates will be listed below
-
Authors
Buschhaus, Johanna M.
Rajendran, Shrila
Humphries, Brock A.
Cutter, Alyssa C.
Muñiz, Ayşe J.
Ciavattone, Nicholas G.
Buschhaus, Alexander M.
Cañeque, Tatiana https://orcid.org/0000-0002-1110-0643
Nwosu, Zeribe C.
Sahoo, Debashis
Bevoor, Avinash S.
Shah, Yatrik M. https://orcid.org/0000-0002-2487-4816
Lyssiotis, Costas A. https://orcid.org/0000-0001-9309-6141
Ghosh, Pradipta
Wicha, Max S. https://orcid.org/0000-0003-4180-7727
Rodriguez, Raphaël https://orcid.org/0000-0001-7668-446X
Luker, Gary D. https://orcid.org/0000-0001-6832-2581
- License Information
-
More Information
Article History
Received: 7 March 2022
Revised: 31 May 2022
Accepted: 13 June 2022
First Online: 22 June 2022
Competing interests
: CAL has received consulting fees from Astellas Pharmaceuticals, Odyssey Therapeutics, and T-Knife Therapuetics, and is an inventor on patents pertaining to Kras regulated metabolic pathways, redox control pathways in pancreatic cancer, and targeting the GOT1-pathway as a therapeutic approach (US Patent No: 2015126580-A1, 05/07/2015; US Patent No: 20190136238, 05/09/2019; International Patent No: WO2013177426-A2, 04/23/2015). GDL has received research funding from InterAx Biotech AG and Polyphor (now part of Spexis). The remaining authors declare no competing interests.
